Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India for the treatment of mild to moderate Covid-19 in patients who are at high risk.
The Antibody Cocktail, which is a mix of Casirivimab and Imdevimab, is priced at Rs 59,750 per dose.
The drugmakers said that the first batch of the Antibody Cocktail is now available in India while a second batch will be made available by mid-June.
"In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients," Cipla and Roche said in a joint statement. The drug will be available through leading hospitals and Covid treatment centres.
The Central Drugs Standards Control Organisation had recently provided an emergency use authorisation for the Antibody Cocktail in India. It has also received nod in the US and several EU countries.
The antibody cocktail is to be administered for the treatment of mild to moderate Covid-19 in adults and kids above 12 years of age.
The has shown to reduce the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days, Cipla and Roche said.